Cargando…

Dopaminergic Modulation of Biological Motion Perception in patients with Parkinson’s disease

Parkinson’s disease (PD) is a progressive neurodegenerative disorder pathologically characterized by a selective loss of dopaminergic neurons in the substantia nigra. In previous studies, greater attention was paid to impairments in motor disturbances in contrast to impairments of cognitive function...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tingting, Hu, Panpan, Cao, Ruihua, Ye, Xing, Tian, Yanghua, Chen, Xianwen, Wang, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579208/
https://www.ncbi.nlm.nih.gov/pubmed/28860519
http://dx.doi.org/10.1038/s41598-017-10463-2
_version_ 1783260665099583488
author Liu, Tingting
Hu, Panpan
Cao, Ruihua
Ye, Xing
Tian, Yanghua
Chen, Xianwen
Wang, Kai
author_facet Liu, Tingting
Hu, Panpan
Cao, Ruihua
Ye, Xing
Tian, Yanghua
Chen, Xianwen
Wang, Kai
author_sort Liu, Tingting
collection PubMed
description Parkinson’s disease (PD) is a progressive neurodegenerative disorder pathologically characterized by a selective loss of dopaminergic neurons in the substantia nigra. In previous studies, greater attention was paid to impairments in motor disturbances in contrast to impairments of cognitive function in PD that was often ignored. In present study, a duration discrimination paradigm was used to assess global and local biological motion (BM) perception in healthy controls(HCs) and PD patients with and without dopamine substitution treatment (DST). Biological motion sequences and inanimate motion sequences (inverted BM sequences) were sequentially presented on a screen. Observers were required to verbally make a 2-alternative forced-choice to indicate whether the first or second interval appeared longer. The stimuli involved global and local BM sequences. Statistical analyses were conducted on points of subjective equality (PSE). We found significant differences between untreated PD patients and HCs as well as differences between global and local BM conditions. PD patients have a deficit in both global and local BM perception. Nevertheless, these two BM conditions can be improved under DST. Our data indicates that BM perception may be damaged in PD patients and dopaminergic medication is conducive to maintain the BM perception in PD patients.
format Online
Article
Text
id pubmed-5579208
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-55792082017-09-06 Dopaminergic Modulation of Biological Motion Perception in patients with Parkinson’s disease Liu, Tingting Hu, Panpan Cao, Ruihua Ye, Xing Tian, Yanghua Chen, Xianwen Wang, Kai Sci Rep Article Parkinson’s disease (PD) is a progressive neurodegenerative disorder pathologically characterized by a selective loss of dopaminergic neurons in the substantia nigra. In previous studies, greater attention was paid to impairments in motor disturbances in contrast to impairments of cognitive function in PD that was often ignored. In present study, a duration discrimination paradigm was used to assess global and local biological motion (BM) perception in healthy controls(HCs) and PD patients with and without dopamine substitution treatment (DST). Biological motion sequences and inanimate motion sequences (inverted BM sequences) were sequentially presented on a screen. Observers were required to verbally make a 2-alternative forced-choice to indicate whether the first or second interval appeared longer. The stimuli involved global and local BM sequences. Statistical analyses were conducted on points of subjective equality (PSE). We found significant differences between untreated PD patients and HCs as well as differences between global and local BM conditions. PD patients have a deficit in both global and local BM perception. Nevertheless, these two BM conditions can be improved under DST. Our data indicates that BM perception may be damaged in PD patients and dopaminergic medication is conducive to maintain the BM perception in PD patients. Nature Publishing Group UK 2017-08-31 /pmc/articles/PMC5579208/ /pubmed/28860519 http://dx.doi.org/10.1038/s41598-017-10463-2 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Liu, Tingting
Hu, Panpan
Cao, Ruihua
Ye, Xing
Tian, Yanghua
Chen, Xianwen
Wang, Kai
Dopaminergic Modulation of Biological Motion Perception in patients with Parkinson’s disease
title Dopaminergic Modulation of Biological Motion Perception in patients with Parkinson’s disease
title_full Dopaminergic Modulation of Biological Motion Perception in patients with Parkinson’s disease
title_fullStr Dopaminergic Modulation of Biological Motion Perception in patients with Parkinson’s disease
title_full_unstemmed Dopaminergic Modulation of Biological Motion Perception in patients with Parkinson’s disease
title_short Dopaminergic Modulation of Biological Motion Perception in patients with Parkinson’s disease
title_sort dopaminergic modulation of biological motion perception in patients with parkinson’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579208/
https://www.ncbi.nlm.nih.gov/pubmed/28860519
http://dx.doi.org/10.1038/s41598-017-10463-2
work_keys_str_mv AT liutingting dopaminergicmodulationofbiologicalmotionperceptioninpatientswithparkinsonsdisease
AT hupanpan dopaminergicmodulationofbiologicalmotionperceptioninpatientswithparkinsonsdisease
AT caoruihua dopaminergicmodulationofbiologicalmotionperceptioninpatientswithparkinsonsdisease
AT yexing dopaminergicmodulationofbiologicalmotionperceptioninpatientswithparkinsonsdisease
AT tianyanghua dopaminergicmodulationofbiologicalmotionperceptioninpatientswithparkinsonsdisease
AT chenxianwen dopaminergicmodulationofbiologicalmotionperceptioninpatientswithparkinsonsdisease
AT wangkai dopaminergicmodulationofbiologicalmotionperceptioninpatientswithparkinsonsdisease